You are currently viewing our desktop site, do you want to download our app instead?
Moneyweb Android App Moneyweb iOS App Moneyweb Mobile Web App

NEW SENS search and JSE share prices

More about the app

AstraZeneca new variant vaccine only likely available in November/December

‘The SA variant is already present in the UK, and the scientists at Oxford are already working on a new version of the vaccine. So it’s sky-high priority’ – Magda Wierzycka, co-CEO of Sygnia.

NOMPU SIZIBA: Following the disheartening news that studies have now shown that the AstraZeneca Covid-19 vaccine is not able to effectively prevent mild to moderate cases of the 501Y variant Version 2, commonly known as the South African variant, and the government’s subsequent decision to put on hold the vaccination rollout with the same vaccine, we speak to a businesswoman who has been invested in the creation of the AstraZeneca vaccine. My colleague, Ryk van Niekerk, caught up with Magda Wierzycka, a co-CEO at the passive investment company Sygnia.

RYK VAN NIEKERK: Magda, Thank you so much for joining me. What do you think of this development?

MAGDA WIERZYCKA: Hi, Ryk. Obviously the news is disappointing in that I think we’ve had much help in the AstraZeneca vaccine, particularly … because of the pricing level. It is the most cost-effective vaccine we could have gained access to potentially. There are a couple of points.

I think one is that the study that has been done has been done on a very small size of population. I think it was 1 100 people that were actually vaccinated with the existing AstraZeneca vaccine. We are looking at South Africa having procured 1.3 million doses of the vaccine. Given that there are no results in terms of whether the vaccine works against severe cases of the South African strain of Covid-19, I think it would be a pity not to waste the 1.5 million doses as opposed to actually using them to vaccinate medical personnel right now, and then almost have a much bigger sample size that you are observing on a live basis in terms of the effectiveness of the vaccine.

But, having said that, Oxford has already said that it is working on a variation of the vaccine which would work against the new variant or the new variants, including the Brazilian variant, and that they should have a new version of the vaccine available by autumn. In fact, I heard Sir John Bell saying [by] September 1 they should have the new formula, if you like, available.

RYK VAN NIEKERK: Magda, have Oxford or AstraZeneca been involved or have they done their own research into the effectiveness of this vaccine against the South African variant?

MAGDA WIERZYCKA: Ryk, I believe that the vaccine trial, that of the testing that was done, was done as a collaborative effort between the University of Oxford and the University of the Witwatersrand, because the actual trial has to be done in a geographical location where the strain of the virus it’s testing against is prevalent, because in all of these trials you cannot actually take people and intentionally expose them to the virus. So they have to come into contact with the virus though natural means.

And, as a consequence, you actually have to run these trials in the location where there is a high probability of the individual people who have been injected with the vaccine – I don’t want to call them subjects – people who have kindly volunteered for these trials where there’s a high probability of their coming into contact with the virus. So the trials were run in South Africa.

What I think is very positive – let me rephrase, nothing is positive in the world of Covid-19. But in the UK, they have now picked up some very random testing over 147 cases of, I prefer to call it, the 501-V2 variant as opposed to the South African variant. And in fact the same variant has been picked up in I think 67 countries now. But because it has been picked up in the UK, there are growing fears that it is obviously much more prevalent than what the testing shows, and consequently there is much more impetus on Oxford to adjust the vaccine to work against the South African variant. That obviously is positive for South Africa because we can then start focusing on procuring the new vaccine.

RYK VAN NIEKERK: The key is, when will we get the new vaccine that will be a lot more effective. What has been the reaction from AstraZeneca? I’m sure you’ve been in contact with them. How do they view this research finding?

MAGDA WIERZYCKA: Well, obviously they are disappointed, because ideally you would have liked to have seen a much greater level of effectiveness of the vaccine against the mild and moderate versions of the disease. But again, being an actuary and a statistician, I do believe that a sample of 1 100 people is a very, very small statistical sample.

Nonetheless, they are hopeful;  and it is a hope because, again, they tested the vaccine on very young people. The median age was 31. They are hopeful that the vaccine can still be effective against severe versions of Covid-19, which is why I said right at the beginning that I think we shouldn’t waste the 1.5 million doses of the AstraZeneca vaccine. We should actually start inoculating frontline personnel.

The vaccine is safe. There are no safety issues. And the same thing will happen in the UK.

They’re rolling out the standard AstraZeneca vaccine as is (in the UK), and then the booster shots which they will be developing will cover the South African variant.

So we could take exactly the same approach, use the 1.5 million doses that we have available, while focusing on procuring the new version of the AstraZeneca vaccine, which, if you take into account manufacturing processes, unfortunately will probably only be available in November/December.

And at the same time, the only alternative really, because the Johnson & Johnson and Novavax are also showing not fantastic results. So the vaccines that potentially would work in South Africa, just because they have such high level of efficacy, are the Moderna and Pfizer vaccines, the RNA vaccines. But there is the logistical problem of storing things at ‑70 degrees, and the cost is astronomical.

So, given that we’ve just gone through a wave in which the medical community believes that the level of natural immunity that has developed in South Africa is probably in the range of between 20% to 30% already. So 20% to 30% of the population already has antibodies. Those antibodies are likely to last – again it’s guesswork, because they’re not sure – between three and six months.

We do have some level of natural protection that has developed in South Africa because we have gone through these two kind of waves already.

RYK VAN NIEKERK: But there are a  few other aspects which I am concerned about. Number one, how high on the priority list is the South African strain or is AstroZenica. Will we get the due attention from AstraZeneca and the research to actually find a vaccine that is really effective?

And number two, we’re talking about the end of the year here – October, November, December. What happens if we see another mutation?

MAGDA WIERZYCKA: A very good question. First of all, in terms of priority, it’s priority number one. And it’s priority number one because these variations and mutations in the virus at a worldwide problem, and it’s a little bit like governments playing Whack-a-mole. So in terms of the UK, they are acutely aware that obviously the South African variant is already present in the UK, and the scientists at Oxford are already working on a new version of the vaccine. So it’s sky-high priority, definitely. What the South African government needs to do is it needs to prioritise the procurement of the vaccine, which is a completely different debate – because obviously we were not very successful in the first attempt.

Now, in terms of the timelines…the AstraZeneca new variant vaccine will only be available in November/December. So I think we need to prepare for another phase or cycle of the virus.

And I think there, again, the medical community is predicting May/June/July as  potentially there being a third wave. So potentially a third version of some kind of lockdown measures will be imposed.

But, having said that, if you look at what has happened in the second wave, the second wave – and not to, again, in any way underestimate the impact that it has on families who have lost loved ones – but if you actually just look at it from a very kind of top-down perspective, the second wave hit South Africa very quickly, very sharply, and waned very quickly, which is actually a positive. It’s not a wave that has lingered on and on and on. It literally rose up, and the numbers started falling down dramatically. So I think that in any kind of a third wave there’s a potential that a similar thing happens, and that the natural immunity that the South African population already has, be it well below that required for what’s called herd immunity, and the fact that so many people have had Covid already, means that they do have antibodies, they do have natural protection; and hence potentially the impact of any third wave will be much smaller than the previous two.

NOMPU SIZIBA: That was Magda Wierzycka. She’s a co-CEO at Sygnia.

Please consider contributing as little as R20 in appreciation of our quality independent financial journalism.

AUTHOR PROFILE

COMMENTS   16

Sort by:
  • Oldest first
  • Newest first
  • Top voted

You must be signed in to comment.

SIGN IN SIGN UP

Another feather in your torn cap ANC!

Add this to the list of all your failures and you might be in the running for a Nobel Peace Price, together with “our” Cuban health workers

Hang on, there is plenty to criticise, but the government tried its best to slow transmission of the virus. Granted, it was to “flatten the curve” not to prevent mutations, but who knows where the mutations would have been if they had listened to those who wanted the virus to run rampant, as many “experts” were suggesting.

Granted, however there’s a private organization called Panda, (highly educated and skilled people) who’s advise, had it been followed would have had better results without the economic devastation..Government chose their own course

This Government has proved time and again it’s not able to give us the people what we deservedly are entitled to

Education, SAA, Eskom and failed Municipalities with raw sewage and potholes lining our streets are a mere handful of examples

Their problem is self enrichment..This vaccine rollout is just another way of of tenderpreneurs waiting with baited breath to line their pockets..So two things are currently on hold:

A vaccine rollout and
Corruption on a grand scale

“…but the government tried its best to slow transmission of the virus”

No….this government knee jerked its decisions on what other countries were trying ..and failed. They had no project managed team whats so ever….except for NDZ and her family

This government ultimately had no plan…it was much like a hatch job over “chicken-licken”

@steve roux I thought Panda has made numerous errors, and was recently abandoned by its overseas advisors

How about the wanna be doctors we sent for training to Cuba THEN CALLED THEM BACK BEFORE FINISHING??? I know Cuba has one of the best medical colleges in the world. NOT

True, however the SG has a long history of dealings with the Cubans

The ANC chose to bring in Cuban doctors as opposed to thousands of our own, jobless and frustrated

And CR wants to award them with a Nobel peace price, when our own medical staff and frontline workers did as much if not more

Never trust a corrupt Politician..In our case the bulk of the ANC

WE have Aspen…around the corner that can do this vaccine for us.
Has a proper supply chain…cold storage … etc

And yet the ANC is messing around ????

I guess …a way to loot is on the cards

…available in Nov/Dec 2021, or 2022?

I guess, all this is too much to ask for a political party who has its roots as a terrorist organisation! What can one expect from thugs?

Disappointing…

Lots of speculation in this interview.

Here’s some more speculation: the world will react to a further mutation in SA by blockading South(ern) Africa to passengers. The risk to the economic recovery and health of the rest of the world of a vaccine evading strain would be too great.

Y2K all over again 46,473 deaths with 57 million people equates to .081% death rate. THE FLU IS 4.2%. Does anyone else see this?????????

1. Would you send your parents to a hospital for treatment? Knowing that the chance of it affecting them is high.
2. The pandemic must not be measured by deaths alone. Those fortunate ones that made it out of ICU; may take over 3 months to fully recover.

one advantage of being available later is that any new variants’ that pop-up (in the meantime) can be taken into account when the amended AZ vaccine is re-released. AZ may (then) become the go-to vaccine

AstraZeneca had a lot of trouble with their clinical trials, even before this SA variant hit the news. They will need to address those issues as well as dealing with the new variants.

That’s strange. It only took ten months to develop a vaccine starting from scratch – but now it will take another ten months just to “tweak” it?

On my side I still don’t see why bringing doctors from Cuba was a good decision short term or long term! We have been told that Cuba health system is top notch and they also do not get affected by the diseases that mostly affect SA citizens more than others(So do they get these unique experiences?).
We train our doctors in different countries like Cuba and China. We spend a lot of money doing this but still the countries that train them are quick to be called in to assist because there are no skills like Data Analytics and hands on skills, how is this possible?
The ROI on these trainings are what exactly!
The minister of health and CR should stop playing with us including the approved the “Noble” price nomination.

Are we going to import skills again when another disease visits us!

End of comments.

LATEST CURRENCIES  

USD / ZAR
GBP / ZAR
EUR / ZAR

Podcasts

INSIDER SUBSCRIPTIONS APP VIDEOS RADIO / LISTEN LIVE SHOP OFFERS WEBINARS NEWSLETTERS TRENDING PORTFOLIO TOOL CPD HUB

Follow us:

Search Articles: Advanced Search
Click a Company: